Efficacy Study of Vx001 Vaccine in NSCLC Patients

Update Il y a 5 ans
Reference: NCT01935154

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Patients with stage IV or recurrent stage I-III NSCLC with documented disease control (objective response or stable disease) within 3 weeks after platinum based 1st line chemotherapy; only HLA-A*0201 positive patients with TERT expressing tumors will be included. The objective of the trial is survival rate at 12 months.


Inclusion criteria

  • Non-small Cell Lung Cancer Metastatic

Links